title: Circulating adiponectin and breast cancer risk: a systematic review and meta-analysis.
abstract: BACKGROUND
  We conducted a meta-analysis in order to investigate whether circulating adiponectin, an insulin-sensitizing hormone produced by adipocytes, is associated with breast cancer risk.
  
  
  METHODS
  A systematic literature search was performed in PubMed, Medline, EMBASE, ISI Web of Knowledge and the Cochrane Library. The summary relative risk (SRR) was calculated by pooling the different study-specific estimates using the random effect models. Meta-regression, subgroup and sensitivity analyses were carried out to investigate between-study heterogeneity and to test publication bias.
  
  
  RESULTS
  Data from 15 observational studies, published between 2003 and April 2013 for a total of 4249 breast cancer cases, were analysed. The SRR for the 'highest' vs 'lowest' adiponectin levels indicated a 34% reduction in breast cancer risk [95% confidence interval (CI): 13%-50%]. Between-study heterogeneity was not substantial (I(2)=53%). Ten studies were included in the dose-response analysis: the SRR for an increase of 3 µg/ml of adiponectin corresponded to a 5% risk reduction (95% CI: 1%-9%). The comparison between 'highest' and 'lowest' levels of adiponectin showed an inverse association in postmenopausal women (SRR=0.80; 95% CI: 0.63-1.01) and an indication of an inverse relationship in premenopausal women (SRR=0.72, 95% CI: 0.30-1.72). No evidence of publication bias was found.
  
  
  CONCLUSIONS
  Low circulating adiponectin levels are associated with an increased breast cancer risk. However, properly designed studies are needed to confirm the role of adiponectin as breast cancer biomarker, and clinical trials should be performed to identify those interventions that may be effective in modulating adiponectin levels and reducing breast cancer risk.
authors.affiliation: Division of Cancer Prevention and Genetics and Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy.
authors.forename: Debora
authors.initials: D
authors.lastname: Macis
authors.affiliation: Division of Cancer Prevention and Genetics and Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy.
authors.forename: Aliana
authors.initials: A
authors.lastname: Guerrieri-Gonzaga
authors.affiliation: Division of Cancer Prevention and Genetics and Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy sara.gandini@ieo.it.
authors.forename: Sara
authors.initials: S
authors.lastname: Gandini
mesh_terms: D052242:Adiponectin / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000453:epidemiology; D005260:Female; D006801:Humans; D012306:Risk
chemical_list: D052242:Adiponectin; D014408:Biomarkers, Tumor
keywords: Circulating adiponectin; biomarker; breast cancer risk
references.citation: Stat Med. 2002 Jun 15;21(11):1539-58
references.pmid: 12111919
references.citation: J Clin Oncol. 2012 Jan 10;30(2):164-71
references.pmid: 22162568
references.citation: Cancer Epidemiol. 2010 Oct;34(5):580-6
references.pmid: 20579950
references.citation: Eur J Cancer Prev. 2014 May;23(3):158-65
references.pmid: 23929213
references.citation: Int J Cancer. 2009 Dec 1;125(11):2704-10
references.pmid: 19588485
references.citation: Breast Cancer Res Treat. 2009 Feb;113(3):567-76
references.pmid: 18330696
references.citation: Cancer Lett. 2006 Jun 8;237(1):109-14
references.pmid: 16019138
references.citation: Breast Cancer Res Treat. 2010 Jan;119(2):367-7
references.pmid: 19842034
references.citation: Clin Cancer Res. 2003 Nov 15;9(15):5699-704
references.pmid: 14654554
references.citation: Cancer Causes Control. 2002 Oct;13(8):741-51
references.pmid: 12420953
references.citation: Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83
references.pmid: 10092513
references.citation: Expert Opin Investig Drugs. 2006 Aug;15(8):917-31
references.pmid: 16859394
references.citation: Cancer Prev Res (Phila). 2013 Mar;6(3):188-95
references.pmid: 23466816
references.citation: J Clin Endocrinol Metab. 2007 Mar;92(3):1041-8
references.pmid: 17192291
references.citation: Nutr Rev. 2011 Oct;69(10):599-612
references.pmid: 21967160
references.citation: J Natl Cancer Inst. 2009 Jan 7;101(1):48-60
references.pmid: 19116382
references.citation: J Clin Endocrinol Metab. 2007 Apr;92(4):1510-6
references.pmid: 17213279
references.citation: Stat Med. 2001 Feb 28;20(4):641-54
references.pmid: 11223905
references.citation: PLoS One. 2013 Aug 22;8(8):e73183
references.pmid: 23991180
references.citation: Menopause. 2013 Aug;20(8):845-51
references.pmid: 23481121
references.citation: Lancet. 2008 Feb 16;371(9612):569-78
references.pmid: 18280327
references.citation: Breast Cancer Res. 2011 Mar 30;13(2):R34
references.pmid: 21450081
references.citation: Indian J Med Res. 2012 Apr;135(4):500-5
references.pmid: 22664497
references.citation: Clin Cancer Res. 2013 Apr 15;19(8):1926-32
references.pmid: 23355630
references.citation: Eur J Cancer. 2011 Jan;47(1):33-43
references.pmid: 20889333
references.citation: Am J Clin Nutr. 2007 Sep;86(3):s858-66
references.pmid: 18265479
references.citation: J Natl Cancer Inst. 2003 Aug 20;95(16):1218-26
references.pmid: 12928347
references.citation: J Clin Oncol. 2012 Jan 10;30(2):124-6
references.pmid: 22162567
references.citation: Cardiovasc Diabetol. 2011 Jan 28;10:13
references.pmid: 21276223
references.citation: Eur J Cancer Prev. 2010 Jan;19(1):55-60
references.pmid: 19927000
references.citation: J Korean Med Sci. 2007 Feb;22(1):117-21
references.pmid: 17297263
references.citation: Med Oncol. 2011 Dec;28(4):1288-95
references.pmid: 20625941
references.citation: Endocr Relat Cancer. 2007 Sep;14(3):669-77
references.pmid: 17914097
references.citation: J Clin Epidemiol. 2008 Apr;61(4):344-9
references.pmid: 18313558
references.citation: Endocr Relat Cancer. 2011 Mar 03;18(2):235-44
references.pmid: 21263044
references.citation: Am J Epidemiol. 1992 Jun 1;135(11):1301-9
references.pmid: 1626547
references.citation: JAMA. 2000 Apr 19;283(15):2008-12
references.pmid: 10789670
references.citation: J Clin Endocrinol Metab. 2001 May;86(5):1930-5
references.pmid: 11344187
references.citation: BMC Cancer. 2013 Feb 04;13:54
references.pmid: 23374911
references.citation: J Clin Oncol. 2011 Jan 1;29(1):32-9
references.pmid: 21115858
references.citation: Am J Epidemiol. 2000 Sep 15;152(6):514-27
references.pmid: 10997541
references.citation: Am J Epidemiol. 2013 Jan 1;177(1):3-13
references.pmid: 23171880
references.citation: Cell. 2004 Jan 23;116(2):337-50
references.pmid: 14744442
references.citation: Asian Pac J Cancer Prev. 2010;11(1):61-6
references.pmid: 20593932
references.citation: Asian Pac J Cancer Prev. 2012;13(1):395-8
references.pmid: 22502709
references.citation: Chin Med J (Engl). 2007 Sep 20;120(18):1592-6
references.pmid: 17908478
references.citation: Stat Med. 2002 Feb 28;21(4):589-624
references.pmid: 11836738
references.citation: J Clin Endocrinol Metab. 2004 Mar;89(3):1102-7
references.pmid: 15001594
references.citation: Epidemiol Rev. 1987;9:1-30
references.pmid: 3678409
references.citation: Int J Cancer. 2004 Sep 20;111(5):762-71
references.pmid: 15252848
references.citation: J Clin Oncol. 2012 Jan 10;30(2):151-7
references.pmid: 22162577
references.citation: J Clin Oncol. 2002 Jan 1;20(1):42-51
references.pmid: 11773152
references.citation: J Clin Endocrinol Metab. 2010 Feb;95(2):911-9
references.pmid: 19996310
references.citation: Cancer Prev Res (Phila). 2012 Apr;5(4):583-92
references.pmid: 22318751